Multiparametric quantitative phase imaging as a tool to assess breast cancer response to therapy in patient-derived models

Functional precision medicine aims to identify effective treatments for patients without targetable mutations. Current research in oncology screens patient-derived models of cancer using endpoint assays. However, these assays fail to capture dynamic responses and tumor heterogeneity. We developed multiparametric quantitative phase imaging (mQPI), a labelfree technique, to screen single cells in real-time. Our work shows mQPI correlates with endpoint assays in measuring drug response in cells from patient derived xenograft organoids (PDxOs), while also capturing time of response and singlecell heterogeneity. Additionally, we demonstrate that mQPI can differentiate organoids that come from the same patient, but which originated from different sites.